Eli Lilly and Company (NYSE:LLY) Shares Climb 2.8% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 2.8% on Thursday. The company traded as high as $1,197.79 and last traded at $1,183.2170. 2,404,559 shares were traded during trading, a decline of 20% from the average session volume of 3,013,247 shares. The stock had previously closed at $1,150.99.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves once-weekly insulin: The FDA approved Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes. The treatment offers seven days of basal insulin coverage and could reduce injection frequency versus daily insulin, expanding Lilly’s diabetes portfolio and creating a potential commercial growth opportunity. FDA approves Lilly’s once-weekly insulin injection
• Positive Sentiment: Olumiant gains pediatric approval: The FDA expanded Olumiant’s label to include patients 12 and older with severe alopecia areata. Phase 3 data showed substantial scalp, eyebrow and eyelash regrowth, broadening the drug’s addressable market beyond adults. FDA approves Lilly’s Olumiant for pediatric patients
• Positive Sentiment: China research partnership: Lilly agreed to pay InnoCare $100 million upfront under a research collaboration that could generate up to approximately $3.35 billion in payments and milestones across as many as five undisclosed drug targets. The deal strengthens Lilly’s pipeline, although much of the potential value remains contingent on successful development. China’s InnoCare and Eli Lilly collaboration
• Positive Sentiment: Manufacturing expansion: Lilly broke ground on a planned $6.5 billion Houston manufacturing facility, signaling continued investment in capacity to support demand for its diabetes, obesity and other medicines. Eli Lilly breaks ground on Houston manufacturing plant
• Neutral Sentiment: Obesity-drug leadership remains central: Coverage says Lilly is gaining ground on Novo Nordisk in GLP-1 treatments, including the emerging obesity-pill market. However, increasing competition, new treatment options and questions about long-term patient retention could pressure future growth expectations. Novo and Eli Lilly obesity drugs
• Negative Sentiment: Insider selling and valuation risks: Recent reported insider transactions included sales by several executives, while LLY trades at a premium valuation. These factors may limit upside if product launches or pipeline programs fail to meet elevated expectations.

Wall Street Analyst Weigh In

Several analysts have weighed in on LLY shares. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research report on Friday, August 7th. Morgan Stanley reissued an “overweight” rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Sanford C. Bernstein lifted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. TD Cowen restated a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday. Finally, Citigroup lifted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,308.39.

Eli Lilly and Company Stock Up 0.2%

The stock has a market cap of $1.11 trillion, a PE ratio of 39.74, a P/E/G ratio of 1.45 and a beta of 0.50. The business has a 50 day moving average price of $1,177.12 and a 200 day moving average price of $1,082.78. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 36.62 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. This represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by company insiders.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently made changes to their positions in the business. Integrity Financial Corp WA increased its holdings in Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after acquiring an additional 8 shares in the last quarter. Willner & Heller LLC grew its position in shares of Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after purchasing an additional 9 shares during the period. Aspiring Ventures LLC increased its stake in shares of Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after purchasing an additional 9 shares in the last quarter. Wealthspan Partners LLC raised its position in shares of Eli Lilly and Company by 0.4% during the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after purchasing an additional 9 shares during the last quarter. Finally, Navigoe LLC lifted its stake in Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after buying an additional 9 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.